Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 4/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251804 | 0.85 | TNF (0.56) | TNF | |
| SCHEMBL2336285 | 0.83 | ALDH1A1 (0.45) | CNR2ALDH1A1 | |
| SCHEMBL5186888 | 0.81 | CNR2 (0.39) | CNR2ALDH1A1TNFKDM4E | |
| SCHEMBL7181790 | 0.80 | ADORA2B (0.47) | KAT2BCNR2ALDH1A1FAAH | |
| SCHEMBL7178960 | 0.80 | ADORA2B (0.47) | KAT2BCNR2ALDH1A1FAAH | |
| SCHEMBL7178946 | 0.80 | ADORA2B (0.47) | KAT2BCNR2ALDH1A1FAAH | |
| SCHEMBL5269258 | 0.80 | ADORA2B (0.47) | KAT2BCNR2ALDH1A1FAAH | |
| SCHEMBL1948066 | 0.77 | ADORA2B (0.46) | CNR2ALDH1A1KDM4E | |
| SCHEMBL9412552 | 0.75 | TNF (0.53) | ALDH1A1TNF | |
| SCHEMBL11514590 | 0.75 | ALDH1A1 (0.56) | KAT2BCNR2ALDH1A1TNFDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209561-A1 | Xanthine Derivatives with HM74A Receptor Activity | HATLEY RICHARD JONATHAN DANIEL | 2009-08-20 | — | — | US | disclosed |
| US-20090209561-A1 | Xanthine Derivatives with HM74A Receptor Activity | HATLEY RICHARD JONATHAN DANIEL | 2009-08-20 | — | — | US | disclosed |
| US-20090209561-A1 | Xanthine Derivatives with HM74A Receptor Activity | HATLEY RICHARD JONATHAN DANIEL | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209561-A1 | Xanthine Derivatives with HM74A Receptor Activity | XDH, HCAR1, GPR84 | KAT2B 4541/4885TLR7 149/4885CNR2 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.